Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad

Shots: FUJI YAKUHIN to receive up front, development & commercial milestones and will manufacture the formulation of dotinurad and supply it to Eisai while Eisai will get exclusive development and marketing rights for therapy and will be responsible for regulatory submission in China FUJI YAKUHIN is expecting the maximum value of dotinurad in China by […]Read More


The US FDA Upgrades the Purple Book to Assist the

Shots: The US FDA is upgrading the Purple Book by changing it from the current list format to a searchable online database. The FDA has released the first phase that contains information on FDA-licensed biosimilar and interchangeable products along with their reference products The further release of phases will expand the number of FDA-licensed biological […]Read More


Takeda Exercises its Exclusive Option to Acquire PvP Biologics for

Shots: Takeda acquires PvP Biologics following the P-I proof-of-mechanism study of TAK-062 (Kuma062) to treat uncontrolled celiac disease. Takeda exercises its option to acquire by paying ~$330M as development & regulatory milestone including $35M up front In 2017, the companies collaborated to develop novel therapies for celiac disease, under which Takeda got exclusive option to […]Read More


WuXi Biologics and Vir Biotechnology Collaborate for the Global Development

Shots: The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development Following the regulatory approvals, Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies The collaboration accelerates the […]Read More


Genentech Collaborates with Bicycle Therapeutics to Develop and Commercialize Bicycle-Based

Shots: Bicycle to receive $1.7B including $30M upfront, development & commercialization milestones and royalties on sales of Bicycle based immuno-oncology therapies against multiple targets which will be commercialized by Genentech Bicycle will conduct discovery research and early pre-clinical development phase up to candidate selection while Genentech will further develop and commercialize the therapies, post-selection of […]Read More


FMCNA’s Novalung ECMO System Receives the US FDA’s Approval for

Shots: The US FDA has cleared the Novalung system which eliminates the need for mechanical ventilation by pumping a person’s blood through an oxygenator for gas exchange Novalung is the first extracorporeal membrane oxygenation (ECMO), approved to provide for more than 6hrs. of use as extracorporeal life support with its anticipated availability in the US […]Read More